

# A TRUSTED PARTNERSHIP IN CERVICAL CANCER SOLUTIONS

**BD's adaptable, scalable and customized solutions empower you to meet the needs of the rapidly changing landscape of cervical cancer screening.** Our full suite of advanced cervical screening products and services are designed to provide solutions with your future needs in mind. When you partner with BD Diagnostics, you and your lab will benefit from fully customized, cutting-edge cervical cancer screening solutions.

Ready to see **a real difference?**  
Contact your BD Diagnostics Account Executive today

## References

- 1 Kumar V, Abbas AK, Fausto N. Robbins and Cotran pathologic basis of disease. 7th Ed. Philadelphia, PA: Elsevier Saunders; 2005.
- 2 BD PrepStain™ System product insert.
- 3 ThinPrep® T2000 product insert
- 4 Nance KV. Diagn Cytopathol. 2007; 35:148-153.
- 5 Fremont-Smith M et al. Cancer Cytopathol 2004; 102:269-279.
- 6 Bigras G et al. J Lower Genital Tract Disease 2003; 7:168-174.
- 7 Moriarty AT et al. Arch Pathol Lab Med 2009; 133:1912-1916.
- 8 Sass MA. Acta Cytol. 2004; 48(1):17-22.
- 9 Fontaine D, Narine N, Naugler C. BMJ Open 2012; Apr 13. doi: 10.1136/bmjopen-2012-000847.
- 10 Marino JF, Fremont-Smith, M. J Reprod Med. 2001; 46:353-358.
- 11 Tench, W. J Reprod Med. 2000; 45(11):912-916.
- 12 Ransdell JS, Davey DD, Zaleski S. Cancer Cytopathol 1997; 81:139-143.
- 13 Nygard JF et al. J Med Screen 2004; 11:70-76.
- 14 Rosa M et al. Diagn Cytopathol 2012; Jul 26. doi: 10.1002/dc.22904. [Epub ahead of print]
- 15 Wilbur DC et al. Am J Clin Pathol 2009; 132:767-775.
- 16 BD FocalPoint™ GS Imaging System Package Insert. Data on file. 2012.




**BD Diagnostics**  
Tullastrasse 8-12  
69126 Heidelberg  
Germany  
Tel : 49.6221.305.0

[www.bd.com/europe/ds](http://www.bd.com/europe/ds)

ThinPrep is a trademark of Hologic, Inc.  
BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. ©2013 BD  
XEUR5241-13

# BD SUREPATH™ LIQUID-BASED PAP TEST



Helping all people  
live healthy lives


# CONFIDENCE IN PATIENT CARE

## Early and accurate detection is the key to preventing cervical cancer from progressing

Reliable screening allows for the detection of cancerous and pre-cancerous changes enabling early intervention. For this reason, it is important to use a technology that will give you accurate and actionable results.

### Early detection leads to better outcomes

Cervical cancer 5-year survival rate<sup>1</sup>



Study conducted using conventional smears

### The BD SurePath™ test is the only Pap test to provide

- The highest HSIL+ detection<sup>2-5</sup>
- Fewer UNSATs<sup>2-5</sup>
- Low ASC-US rates<sup>2-5</sup>



### Beginning with sample collection

The BD SurePath™ test is the only PAP that sends 100% of the sample to the laboratory

The rinsing method used by the other LBC can result in up to 37% of the sample being discarded<sup>6</sup>

- 2/3 of all false negatives are the result of cells not being collected and/or not being tested<sup>6</sup>
- A primary reported reason for unsatisfactory samples is an insufficient number of squamous cells<sup>7</sup>


THE HIGHEST  
DISEASE  
DETECTION

### Featuring a Proprietary Cell Enrichment Process

BD's cell enrichment process ensures only the most diagnostically relevant material is presented on the slide.

The BD process separates and removes blood, mucus, and interfering materials from the sample, meaning only the most diagnostically relevant material transfers to the slide.<sup>4, 8</sup>

OF ANY  
PAP TEST




Ready to see **a real difference?**

Contact your BD Diagnostics Account Executive today

# ACTIONABLE INFORMATION TO IMPROVE PATIENT MANAGEMENT

BD is committed to helping improve clinical decisions by increasing the accuracy and actionability of lab results.


Percent change in UNSAT rates compared to conventional Pap



BD PrepStain™ System product insert, Table 14. T2000 product insert, Table 13.


The BD SurePath™ test consistently demonstrated to lower the UNSAT slide rate — as repeatedly shown in many studies<sup>7-11</sup>

Percentile reporting rates for UNSAT Pap tests by method



In a survey of 373 responding CAP laboratories, the BD SurePath™ Liquid-based Pap consistently demonstrated the lowest UNSAT rates versus all other Pap methods<sup>7</sup>

ASC-US rate<sup>3,4</sup>



BD PrepStain™ System product insert, Table 1. T2000 product insert, Table 10.

The BD SurePath™ test allows a pathologist to accurately distinguish true cytologic abnormalities, as evidenced by the BD SurePath™ test's low ASC-US rates.<sup>2</sup>

It has been reported that up to 30% of women may be lost to follow-up when they are called back for re-sampling after an UNSAT<sup>12</sup>

First-time accuracy – demonstrated by the lowest unsatisfactory rates and low ASC-US results - leads to fewer patient callbacks, reduces patient anxiety, reduces the risk of loss-to-follow-up and removes delays in getting to an actionable result.

UNSAT results have been reported to be associated with 1.6- to 4.0-fold higher risk for CIN 2+<sup>\*13</sup>

Unsatisfactory samples represent a missed opportunity for screening and are more often associated with cervical abnormality.

Fewer unsatisfactory results also reduce the need for reprocessing samples and rescheduling patients, thus lessening the burden on the lab and nursing staff

Reprocessing the other LBC with glacial acetic acid takes time and disrupts staff, while only producing a satisfactory rate of 44%<sup>14</sup>

Ready to see a real difference?  
Contact your BD Diagnostics Account Executive today


\*Study conducted using conventional smears

# MAXIMIZE EFFICIENCY AND FOCUS ON THE CASES THAT MATTER MOST


## Screening BD SurePath™ slides with the BD FocalPoint™ GS Imaging System increases accuracy and efficiency

The BD FocalPoint GS Imaging System assists the laboratory staff to better triage slides for further screening by:

- Using algorithms to determine potential abnormalities and rank slides accordingly<sup>15</sup>
- Focusing attention on the 10 fields of view most likely to contain abnormalities, reducing screening time per slide
- Increasing disease detection and reducing ASC-US rates
- Utilizing Directed QC Technology™ to select slides with the highest likelihood of abnormality for full slide review — improving the quality control process and reducing the risk of missed disease



Higher disease detection with BD SurePath™ slides screened with the BD FocalPoint™ GS Imaging System<sup>16</sup>



Improving the ASC/SIL ratio  
Reducing the ASC/SIL ratio means more actionable results and less uncertainty for patients<sup>16</sup>

**Higher disease detection with BD Surepath™ slides screened with the BD FocalPoint™ GS Imaging System<sup>16</sup>**

- 24.5% increase in cancer sensitivity
- 19.6% increase in HSIL+ sensitivity
- 9.8% increase in LSIL+ sensitivity
- 9.2% increase in ASC-H+ sensitivity

Ready to see **a real difference?**  
Contact your BD Diagnostics Account Executive today